Treating the Adult Patient: Alternative Drug Therapies

  • Paul A. SchmeltzerEmail author


Standard therapy for autoimmune hepatitis can be limited by drug intolerance or inadequate biochemical response. After optimizing drug doses and excluding noncompliance, alternative immunosuppressive agents need to be considered. This chapter will review the role of second-line agents in the treatment of autoimmune hepatitis.


Second line Tacrolimus Cyclosporine Mycophenolate mofetil 


  1. 1.
    Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver. 2016;10(2):177–203.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46(4):1138–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Manns MP, Czaja AJ, Gordon JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):1–31.CrossRefGoogle Scholar
  4. 4.
    Lohse AW, Chazouilleres O, Dalekos G, Drenth J, Heneghan M, Hofer H, Lammert F, Lenzi M. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.CrossRefGoogle Scholar
  5. 5.
    Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53(3):926–34.PubMedCrossRefGoogle Scholar
  7. 7.
    van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8(6):585–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9(12):2681–5.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–206.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Peiseler M, Liebscher T, Sebode M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16:260–7.CrossRefGoogle Scholar
  12. 12.
    Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110(1):271–4.CrossRefGoogle Scholar
  13. 13.
    Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:654–61.PubMedCrossRefGoogle Scholar
  15. 15.
  16. 16.
    Hubener S, Oo YH, Than NN, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14:445–53.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Legue C, Legros L, Kammerer-Jacquet S, et al. Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16:290–1.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    van den Brand FF, van Nieuwkerk CM, Verwer BJ, et al. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Aliment Pharmacol Ther. 2018;48:761–7.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    de Boer YS, van Gerven NM, de Boer NK, et al. Allopurinol safely and effectively optimizes thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 2013;37:640–6.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011;55:636–46.PubMedCrossRefGoogle Scholar
  21. 21.
    Wolf DC, Bojito L, Facciuto M, et al. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54(11):2519–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol. 2014;4(3):221–5.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34(3):335–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6(9):1036–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103(12):3063–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Sharzehi K, Huang MA, Shreibman IR, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory of intolerant to conventional therapy. Can J Gastroenterol. 2010;24(10):588–92.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Roberts SK, Lim R, Strasser S, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16:268–77.PubMedCrossRefGoogle Scholar
  28. 28.
    Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol. 2012;26(9):615–20.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013;38:343–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46(6):1321–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Hanouneh M, Ritchie MM, Ascha M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol. 2019;54(1):76–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Efe C, Hagstrom H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15:1950–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005;5(5):1085–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014;127(11):1128–31.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50(8):1025–31.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Evans JT, Shephard MM, Oates JC, et al. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42(7):862–3.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol. 2010;4(3):502–9.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Santos ES, Arosemena LR, Raez LE, et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26(5):625–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139(11):1484–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Burak KW, Swain MG, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27(5):273–80.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Fujii K, Rokutanda R, Osugi Y, et al. Adult-onset Still’s disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med. 2012;51:1125–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Vallejo SN, Fernandez CJ, Molina PE, et al. Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab. Gastroenterol Hepatol. 2014;37(9):524–6.CrossRefGoogle Scholar
  45. 45.
    Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–34.CrossRefGoogle Scholar
  46. 46.
    Borman MA, Urbanski S, Swain MG. Anti-TNF-induced autoimmune hepatitis. J Hepatol. 2014;61:169–70.PubMedCrossRefGoogle Scholar
  47. 47.
    Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: current and future therapeutic options. Liver Int. 2019;39:1002–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of HepatologyCarolinas Medical Center-Atrium HealthCharlotteUSA

Personalised recommendations